Posted by Michael Wonder on 09 Sep 2020
CANbridge Pharmaceuticals receives Chinese marketing approval for Hunterase first enzyme replacement therapy for Hunter syndrome in China
9 September 2020 - CANbridge Pharmaceuticals announced that it received marketing approval from China’s National Medical Products Administration for Hunterase (idursulfase beta Injection), an enzyme replacement therapy for the long term treatment of patients with mucopolysaccharidosis II (MPS II or Hunter syndrome).
This is the first approved treatment in the CANbridge rare disease portfolio and the first enzyme replacement therapy treatment in China for Hunter syndrome, where it fills an urgent treatment gap. Developed by GC Pharma, Hunterase is designated an orphan drug in the United States and Korea and is marketed in 11 countries.
CANbridge obtained the exclusive licensing rights for Hunterase from South Korea’s GC Pharma in January, 2019 to commercialize the drug in greater China, where it was granted priority review by National Medical Products Administration in September, 2019.
